Omeros (OMER) Fundamentals 2026 — P/E 7.5x, Revenue Analysis | SniperIQ
Omeros (OMER) is a US-listed Healthcare company in Biotechnology with a market capitalization of $703M, trading at $9.71 on the NASDAQ. This SniperIQ fundamentals page covers Omeros's valuation (P/E 7.5x), profitability (net margin 871.0%), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Omeros's market cap?
Omeros (OMER) has a market capitalization of approximately $703M, trading at $9.71 on the NASDAQ. Market cap moves with the live share price.
What is Omeros's P/E ratio?
Omeros's trailing twelve-month P/E ratio is 7.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Omeros?
Omeros runs a net profit margin of 871.0%, a gross margin of -12.4%, and an operating margin of -1063.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does Omeros pay a dividend?
Omeros does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Omeros financially healthy?
Omeros carries a debt-to-equity ratio of -4.90x and a current ratio of 3.03x, with a market beta of 2.55. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Omeros a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Omeros (OMER) the key facts are: market cap $703M, P/E 7.5x, 52-week range 3.44-17.65. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Omeros's full fundamentals live
Get Omeros's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.